Place it in its market
Seven layers of its region's market — rates, credit, stress, liquidity, regime, breadth and sectors — with historical precedents. Public example: Apple and ASML.
See how Context works →On the price, the facts of the public record■Insider buy□Insider sell●Results filed
With an account, also○dividends▲splits◌next earningswith an account
End-of-day prices provided by Twelve Data · One close per session; the series does not update during the trading day.
Latest on record
The most recent facts, as filed.
Up to three of the most recent, checkable facts already loaded on this page, each linked to its source.
- Oct 16, 2026Material event · 8-KFiled by the company itself.Open the filing ↗
- Sep 23, 2026Material event · 8-KFiled by the company itself.Open the filing ↗
- Aug 27, 2026Reported purchase · Form 4Gregory Austin Ciongoli · $499.7KOpen the filing ↗
In numbers
What this profile holds, counted.
Closes · 1 year250
SEC filings on record75716 flagged findings
Reported transactions (Form 4)80since Aug 1, 2024 · and 7 other holdings
Corporate events (8-K)30since Aug 25, 2017
What the record says
Description, identity and filings, each with its source.
Every block cites its source. The colour of a finding marks its category — which document, who filed it — not how much it matters.
Regulatory history
Topics detected in its SEC reports, with the original excerpt.
Each topic is assigned by a classifier over the full filing; the excerpts show where it was detected and are not always enough to verify it. Open the filing to read it in full.
- 2026-05-14share offering or dilution eventrecentOpen filing ↗“…pre-funded warrants were recorded as additional paid-in capital. The Company has issued 652,137 shares of common stock upon the…”
+1 more passage from the same document
- “…corporate advisory services. Liquidity and Capital Resources Sources of Liquidity As of March 31, 2026, we had cash, cash equivalents…”
- 2026-05-14capital return (buybacks/dividends)recentOpen filing ↗“…Second Cap Amount or the termination of the Novartis License, if earlier. The Company has no obligation to repay any amounts to HCR…”
+1 more passage from the same document
- “…no obligation to repay any amounts to HCR under the 2020 Royalty Purchase Agreement if future Zolgensma and Itvisma royalty…”
- 2026-03-05share offering or dilution eventrecentOpen filing ↗“…purchase shares of our common stock at a price of $22.9999 per pre-funded warrant, which equaled the public offering price per share…”
+1 more passage from the same document
- “…of the pre-funded warrants were recorded as additional paid-in capital. During the years ended December 31, 2025 and 2024, the…”
- 2026-03-05capital return (buybacks/dividends)recentOpen filing ↗“…Cap Amount or the termination of the Novartis License, if earlier. The Company has no obligation to repay any amounts to HCR under…”
+1 more passage from the same document
- “…obligation to repay any amounts to HCR under the 2020 Royalty Purchase Agreement if future Zolgensma and Itvisma royalty payments…”
Original excerpts from SEC filings, untranslated. Not advice and not a prediction.
The 25 most recent filings (of 757)
Every SEC filing, newest first, with what it is. Below, each type with its own explanation.
- Oct 16, 268-K ↗Current report · A senior executive left or was appointed new
- Oct 13, 26SCHEDULE 13G ↗Passive stake · JPMORGAN CHASE & CO. · 5.3% · event on Sep 30, 26 new
- Sep 23, 268-K ↗Current report · Entered a material agreement
- Aug 27, 26Form 3 ↗Insider transaction
- Aug 25, 268-K ↗Current report · A senior executive left or was appointed
- Aug 24, 268-K ↗Current report · Communication to the market · Other events
- Aug 6, 2610-Q ↗Quarterly report
- Aug 6, 268-K ↗Current report · Results
- Jul 20, 268-K ↗Current report · Other events
- Jul 17, 26424B5 ↗Securities offering
- Jul 16, 26424B5 ↗Securities offering
- Jul 6, 26SC TO-I/A ↗Merger, acquisition or tender offer · amendment
- Jul 1, 26Form 144 ↗Notice of proposed sale
- Jul 1, 26Form 4 ↗Insider transaction
- Jul 1, 26SC TO-I/A ↗Merger, acquisition or tender offer · amendment
- Jun 29, 268-K ↗Current report · Other events
- Jun 4, 26SCHEDULE 13G/A ↗Passive stake · JPMORGAN CHASE & CO · 4.4% · event on May 29, 26 · amendment
- Jun 3, 26SC TO-I ↗Merger, acquisition or tender offer
757 filings on record, the oldest from Jul 28, 15.
Listing the 25 most recent filings of the 757 on record.
1618
- Oct 16, 26A senior executive left or was appointed8-K 5.02 ↗
- Sep 23, 26Entered a material agreement8-K 1.01 ↗
- Aug 25, 26A senior executive left or was appointed+1 more in the same filing8-K 5.02 ↗
4 material agreements entered2025 – 2026show all 4hide
- Mar 20, 26Entered a material agreement8-K 1.01 ↗
- Aug 7, 25Entered a material agreement+3 more in the same filing8-K 1.01 ↗
- May 19, 25Entered a material agreement+3 more in the same filing8-K 1.01 ↗
- Jan 14, 25Entered a material agreement+2 more in the same filing8-K 1.01 ↗
5 senior executive changes2022 – 2024show all 5hide
- Sep 17, 24A senior executive left or was appointed+2 more in the same filing8-K 5.02 ↗
- Aug 6, 24A senior executive left or was appointed8-K 5.02 ↗
- Jun 13, 24A senior executive left or was appointed+2 more in the same filing8-K 5.02 ↗
- Jan 10, 23A senior executive left or was appointed+1 more in the same filing8-K 5.02 ↗
- Jun 7, 22A senior executive left or was appointed+2 more in the same filing8-K 5.02 ↗
- Mar 25, 22Entered a material agreement8-K 1.01 ↗
- Mar 18, 22A senior executive left or was appointed8-K 5.02 ↗
- Nov 15, 21Entered a material agreement8-K 1.01 ↗
- Sep 13, 21Entered a material agreement+2 more in the same filing8-K 1.01 ↗
- Sep 7, 21A senior executive left or was appointed+1 more in the same filing8-K 5.02 ↗
- Dec 22, 20Entered a material agreement+2 more in the same filing8-K 1.01 ↗
- Jul 2, 20A senior executive left or was appointed+1 more in the same filing8-K 5.02 ↗
8 older filings not shown · The record reaches back to Oct 15, 15.
Corporate events are tracked from 2004-08-23, when the SEC renumbered 8-K items. Earlier filings use an incompatible numbering and are not classified here.
Schedule 13G: short-form filing
The short form, for holders who meet specific requirements: institutional investors, passive investors without a control purpose, or exempt investors. Asset managers and index funds usually file it.
- Redmile Group, LLC9.9%Jun 30, 25SCHEDULE 13G/A ↗3 co-filers on this document — the figure is the largest single stake, not their sum.
- BlackRock, Inc.7.3%Mar 31, 25SCHEDULE 13G/A ↗1 earlier filing
- The Vanguard Group6.0%Dec 31, 24SCHEDULE 13G/A ↗
- JPMORGAN CHASE & CO.5.3%Sep 30, 26SCHEDULE 13G ↗2 earlier filings
- STATE STREET CORPORATION5.3%Mar 31, 26SCHEDULE 13G ↗1 earlier filing
show one more holderhide
- BlackRock Portfolio Management LLC4.1%Dec 31, 25SCHEDULE 13G/A ↗1 earlier filing
Structured 13D/G data starts 2023-12, when the SEC moved these filings to a machine-readable format. Earlier filings exist but are not parsed here.
Sale intention announced
On Jul 1, Stephen J. Pakola filed notice of intent to sell up to $518K. That is about 0.08% of shares outstanding. It is filed under a scheduled plan (10b5-1), arranged in advance.
A notice is not a sale: it may not go ahead, may happen in part, or at a different price.
After the notice, they sold $502K across 2 trades, between Jul 1 and Jul 2, per their Form 4. That is 90% of the shares announced.
- Aug 27, 26Buy$500KGregory Austin Ciongoli↗
- Aug 26, 26Buy$450KGregory Austin Ciongoli↗
- Jul 2, 26Sell$29KSTEVE PAKOLAChief Medical Officer↗
- Jul 1, 26Sell$472KSTEVE PAKOLAChief Medical Officer↗
- Jun 29, 26Sell$216KSTEVE PAKOLAChief Medical Officer↗
- May 11, 26Sell$169KSTEVE PAKOLAChief Medical Officer↗
- Mar 10, 26Sell$53KSTEVE PAKOLAChief Medical Officer↗
- Oct 9, 25Sell$263KCurran SimpsonChief Executive Officer↗
- Sep 29, 25Sell$76KCurran SimpsonChief Executive Officer↗
- Sep 10, 25Sell$77KCurran SimpsonChief Executive Officer↗
Stock compensation, tax and giftsshow the 30 other transactionshide
Stock compensation, tax withholding, option exercises and gifts. They are listed separately and are not included in the purchase and sale totals. The type describes the transaction, not the filer's intent.
- Sep 1, 26Tax$46KMitchell ChanChief Financial Officer↗
- Sep 1, 26Tax$2KCraig MalzahnChief Technology Officer↗
- Aug 25, 26Compensationamount n/aGregory Austin Ciongoli↗
- Aug 1, 26Tax$46KPatrick J. ChristmasChief Strategy & Legal Officer↗
- Aug 1, 26Tax$72KSTEVE PAKOLAChief Medical Officer↗
- Jul 2, 26Compensation$17KSTEVE PAKOLAChief Medical Officer↗
- Jul 1, 26Compensation$289KSTEVE PAKOLAChief Medical Officer↗
- Jul 1, 26Tax$89KCurran SimpsonChief Executive Officer↗
- Jun 30, 26Compensation$15KCurran SimpsonChief Executive Officer↗
- May 29, 26Compensationamount n/aGEORGE MIGAUSKY V↗
- May 29, 26Compensationamount n/aKenneth T. Mills↗
- May 29, 26Compensationamount n/aJennifer Zachary↗
- Feb 1, 26Tax$52KPatrick J. ChristmasChief Strategy & Legal Officer↗
- Feb 1, 26Tax$59KSTEVE PAKOLAChief Medical Officer↗
- Jan 27, 26Compensation$2.9MKenneth T. Mills↗
- Jan 27, 26Tax$3.0MKenneth T. Mills↗
- Jan 6, 26Compensationamount n/aCurran SimpsonChief Executive Officer↗
- Jan 6, 26Compensationamount n/aPatrick J. ChristmasChief Strategy & Legal Officer↗
- Jan 6, 26Compensationamount n/aSTEVE PAKOLAChief Medical Officer↗
- Jan 6, 26Compensationamount n/aMitchell ChanChief Financial Officer↗
- Jan 6, 26Compensationamount n/aCraig MalzahnChief Technology Officer↗
- Jan 2, 26Tax$267KCurran SimpsonChief Executive Officer↗
- Jan 2, 26Tax$141KPatrick J. ChristmasChief Strategy & Legal Officer↗
- Jan 2, 26Tax$263KSTEVE PAKOLAChief Medical Officer↗
- Jan 2, 26Tax$18KCraig MalzahnChief Technology Officer↗
- Dec 31, 25Compensation$7KCurran SimpsonChief Executive Officer↗
- Sep 1, 25Tax$44KMitchell ChanChief Financial Officer↗
- Sep 1, 25Tax$2KCraig MalzahnChief Technology Officer↗
- Aug 1, 25Tax$38KPatrick J. ChristmasChief Strategy & Legal Officer↗
- Jul 1, 25Tax$39KCurran SimpsonChief Executive Officer↗
The full record holds 137 transactions and goes back to Jun 30, 22.
Its sector and its market
Regenxbio Inc. among Health Care companies
The profile shows what is on record. Context and Radar place the company among those of its sector and region.
Browse its neighbours
Other Health Care companies
With an account you also get
- The four engines — growth, trend, risk and context — each with its word and its score.
- The risk band and the sector phase.
- The company's fundamentals and accounts.
- Watchlist: your list of companies, with the «since you follow it» figure.
The research continues
The profile tells the story. The market sets the scene.
From Regenxbio Inc., the path continues in the other areas. Each one is shown with its own example, named in its step.
See what deserves a closer look
Every morning Radar screens the covered companies through a lens and explains why each candidate made the list. Public example: the lists from Aug 11, 2026.
See how Radar works →Keep the why
Follow Regenxbio Inc. in the Watchlist and review what changed since you added it: context, notices and filings. Written theses are coming soon. Public example: Apple.
See an example review →
Coverage
What sits behind this page.
Where each figure comes from and how far it reaches.
- Prices
- End-of-day closes provided by Twelve Data. One close per session; not real time. Closes adjusted for splits.
- Series quality
- 250 clean closes in the period.
- SEC records
- 757 documents on file, from Jul 28, 2015 to Oct 16, 2026.
- Company description
- No description available.
- This page
- Generated on Oct 19, 2026; refreshed through the day.
Start at your own pace
Explore first. Go deeper with access.
Every company's public profile is open. The full reading — context, Radar, watchlist — is inside, in an invitation-only beta.
Compare plans →- No account
This profile for every company we cover: closing prices with the record's facts on the curve, the SEC file in plain language, insider trades included, and links to its sector and exchange.
- Pro
What matters today, with its reason, is free with an account. Pro adds, in the profile, each company's notices and their explanation and the analysis of its insiders; in Radar, all the lenses, which notice each candidate carries, filters by notice type and «no dilution», and the cycle cohort filter; and in Watchlist, more companies and notice changes with their reason.
- Pro+
Adds the Lab: test a hypothesis on comparable cohorts before reusing it; and bring your lenses to Radar.
Are the prices real time?
No. It is one close per session, from the provider and with the date shown on the profile; it does not update during the trading day.
Which SEC documents appear here?
Those filed with the SEC by the company, its insiders and its major shareholders, within our coverage: periodic reports (10-K, 10-Q, 20-F), material events (8-K), proposed sale notices (Form 144), insider transactions (Form 4) and stakes above 5% (13D/13G). Each links to the original on EDGAR.
Why does a European company show no SEC records?
It depends on the company: some European issuers file a 20-F or 6-K with the SEC and others don't. The profile shows whatever is on record; when there is nothing, it says so rather than guessing why. Europe does not yet have a common filing archive like EDGAR in the United States. The EU will open its own, ESAP, in July 2027 (managers' transactions arrive in January 2028), and we plan to add it once it is available.
Before forming a view on a company,
read what is on record.
One close per session. The record in plain language. Its sector and its market one link away. Your judgment when deciding.